Latest Insurance News

Vitura Health’s telehealth arm, Doctors on Demand, has hit a major milestone of over 1 million consultations since FY2024, while delivering sustained EBITDA profitability and a 54% revenue increase over two years to $21.6 million in FY2026 Q1-Q3.

PPK Group has inked a conditional deal to sell its near 40% interest in Craig International Ballistics to German defence firm Mehler for a headline price of A$27.45 million plus a potential earn-out. Completion is targeted by June 30, 2026, subject to regulatory and contractual conditions.

The ACCC has escalated its scrutiny of Insurance Australia Group’s proposed takeover of RAC Insurance, citing potential substantial lessening of competition in Western Australia’s motor and home insurance markets.

The ACCC has escalated its review of Insurance Australia Group’s proposed takeover of RAC Insurance, flagging significant competition concerns in Western Australia’s motor and home insurance markets.

Brambles has faced a mixed Federal Court ruling in a class action over its FY17 profit guidance, with some claims upheld and others dismissed. The financial impact remains uncertain as the company reviews the judgment and potential appeals.

Pacific Edge reported a 2.7% increase in test volumes for Q4 2026 despite operational challenges, supported by growing momentum toward Medicare coverage and expanded commercial payer adoption in the US and Asia Pacific.

QBE Insurance Group Limited has updated its dividend announcement to specify the pricing for its Dividend Reinvestment Plan and Bonus Share Plan, confirming an ordinary dividend of AUD 0.78 per share for the six months ending December 2025.

Vitura Health has appointed Justin James as its new CEO, bringing a wealth of healthcare leadership and a proven track record in specialty therapies to accelerate the company’s transformation.

Vection Technologies has formalised its acquisition of Australian digital transformation firm DXLabs, adding immediate revenue and expanding its footprint across the APAC region.

Aroa Biosurgery has completed its Symphony randomised controlled trial, demonstrating improved healing rates for diabetic foot ulcers compared to standard care. The preliminary results pave the way for clinical adoption and potential US reimbursement.

FINEOS Corporation reports robust FY25 financial performance, driven by subscription revenue growth and embedded AI innovations, setting a confident outlook through FY27.

Challenger Limited’s attempt to acquire Pepper Money has been declined by Pepper’s board, while Challenger moves forward with a $150 million share buy-back program.